BIOLINERX Ltd/S (NASDAQ:BLRX) announced its earnings results on Thursday. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.06), Morningstar.com reports.
Shares of BLRX stock traded down $0.01 on Friday, hitting $0.70. 391,694 shares of the stock traded hands, compared to its average volume of 1,728,884. The stock has a market cap of $78.77 million, a price-to-earnings ratio of -2.59 and a beta of 0.87. BIOLINERX Ltd/S has a twelve month low of $0.67 and a twelve month high of $1.84.
A hedge fund recently bought a new stake in BIOLINERX Ltd/S stock. Fosun International Ltd purchased a new stake in shares of BIOLINERX Ltd/S (NASDAQ:BLRX) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 1,357,415 shares of the biotechnology company’s stock, valued at approximately $1,412,000. Fosun International Ltd owned about 1.27% of BIOLINERX Ltd/S at the end of the most recent quarter. Hedge funds and other institutional investors own 34.69% of the company’s stock.
About BIOLINERX Ltd/S
BioLineRx Ltd., a clinical stage biopharmaceutical development company focused on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions.
Featured Story: Outstanding Shares, Buying and Selling Stocks
Receive News & Ratings for BIOLINERX Ltd/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLINERX Ltd/S and related companies with MarketBeat.com's FREE daily email newsletter.